ReAble completes Iomed acquisition:
This article was originally published in Clinica
Executive Summary
US orthopaedics device manufacturer ReAble Therapeutics has finalised its $22m purchase of drug delivery device company Iomed. The original terms of the merger still apply (see Clinica No 1257, p 14) - Iomed's shareholders will receive $2.75 per share.